Tango Taps Finance Veteran Sung Lee for Board Ahead of Pivotal Cancer Trial

BOSTON, MA – January 05, 2026 – Tango Therapeutics has fortified its leadership team with the appointment of biopharmaceutical finance veteran Sung Lee to its Board of Directors, a strategic move that signals the company's preparation for a critical phase in its growth. The announcement comes as the clinical-stage biotechnology firm gears up to advance its lead precision cancer medicine, vopimetostat, into pivotal late-stage trials.

Mr. Lee, who brings over two decades of high-level financial and strategic experience from industry giants like Gilead Sciences and his current role as CFO of Cytokinetics, joins Tango at a crucial juncture. The company is transitioning from promising early-stage data to the costly and complex world of registrational studies, a path that demands rigorous financial stewardship and savvy investor relations—areas where Lee has a deep and proven track record.

A Strategic Appointment for a Pivotal Moment

The timing of Lee's appointment is anything but coincidental. Tango Therapeutics is on the cusp of initiating a global, randomized pivotal study for vopimetostat in 2026. This step, which follows encouraging clinical results, is the final and most demanding hurdle before a potential submission for regulatory approval. Such trials are notoriously expensive, often costing hundreds of millions of dollars, and require meticulous planning and execution.

Barbara Weber, M.D., Chief Executive Officer of Tango Therapeutics, highlighted the importance of this expertise in the company's official announcement. "We are delighted to welcome Sung Lee to our Board of Directors," she stated. "Sung’s proven track record in corporate strategy, investor relations and finance will be instrumental as we advance our lead program, vopimetostat, into registrational studies and continue to build and evolve our organization to support late-stage clinical development activities."

This move underscores a broader understanding within the biotech industry: navigating late-stage development is as much a financial and strategic challenge as it is a scientific one. Securing a board member with Lee's background is a clear signal to investors that Tango is building the necessary infrastructure to not only fund its ambitious clinical plans but also to potentially scale for commercialization. The company bolstered its finances significantly in October 2025 with a $225 million capital raise, extending its cash runway into 2028, and Lee's oversight will be critical in managing these resources effectively.

The Financial Architect: A Look at Lee's Track Record

Sung Lee’s resume reads like a tour of influential players in the biopharmaceutical landscape. He currently serves as the Executive Vice President and Chief Financial Officer at Cytokinetics, a role he assumed in May 2024. His career is marked by a series of CFO positions at other innovative companies, including Vir Biotechnology, the German firm MorphoSys AG, and Sangamo Therapeutics, where he was instrumental in shaping corporate and financial strategy.

However, it is his nearly 14-year tenure at Gilead Sciences that provides the deepest insight into the experience he brings to Tango's board. At Gilead, a company known for its transformational therapies and blockbuster commercial successes, Lee held positions of increasing responsibility. He ultimately served as Senior Vice President of Financial Planning & Analysis and Head of Investor Relations, giving him a dual perspective on both internal financial management and external market communication. This experience is particularly relevant for a company like Tango, which must balance its R&D burn rate with a compelling narrative for Wall Street.

His early career in the tax advisory business at PwC provided a strong foundational knowledge of finance and taxation. This comprehensive background, spanning Big Pharma, emerging biotech, and foundational financial services, equips him to provide multifaceted guidance on everything from capital allocation and risk management to strategic partnerships and long-term value creation.

Vopimetostat: The High-Stakes Asset at the Center

At the heart of Tango's strategy is vopimetostat, a precision oncology drug with the potential to address a significant unmet need. The therapy is designed to target cancers with a specific genetic vulnerability known as an MTAP-deletion. This genetic marker is found in approximately 10-15% of all human cancers, including a high prevalence in notoriously difficult-to-treat diseases like pancreatic cancer (about 35%) and non-small cell lung cancer (about 15%).

The excitement surrounding the drug intensified in October 2025 when Tango released positive data from its ongoing Phase 1/2 trial. In patients with second-line MTAP-deleted pancreatic cancer, vopimetostat demonstrated a median Progression-Free Survival (PFS) of 7.2 months and an Objective Response Rate (ORR) of 25%. These figures represent a more than twofold improvement compared to historical outcomes with standard-of-care chemotherapy, suggesting a potentially meaningful clinical benefit.

Buoyed by these results and following discussions with the U.S. Food and Drug Administration (FDA), Tango is now preparing for a pivotal study that will enroll around 300 patients globally. The trial will directly compare vopimetostat against standard chemotherapy, setting the stage for a clear verdict on its efficacy. The appointment of a financial heavyweight like Lee is a preparatory step for this high-stakes endeavor, ensuring the company is on solid financial footing as it navigates the path toward a possible New Drug Application.

The Evolving Biotech Boardroom and the Road Ahead

Sung Lee’s appointment is emblematic of a larger trend in the biotechnology sector, where the composition of a company's board is scrutinized as a key indicator of its maturity and strategic foresight. As companies transition from discovery-focused startups to development-stage enterprises, the need for robust financial and commercial expertise at the board level becomes paramount. Investors are increasingly looking for directors who can not only understand the science but also chart a viable course to market.

The role of a finance-focused board member has evolved beyond traditional audit committee functions. In today's volatile market, they are expected to be active partners in capital strategy, investor messaging, and operational scaling. With his experience in scaling organizations and managing multi-billion dollar budgets, Lee is well-suited to this expanded role. His presence on the board provides an additional layer of assurance that Tango’s impressive scientific progress is matched by a sophisticated financial and corporate strategy.

For Tango Therapeutics, the road ahead is clearly defined. The primary focus will be the flawless execution of the vopimetostat pivotal trial and the continued advancement of its other pipeline candidates, such as TNG260 for STK11-mutant cancers. With its science showing promise and its financial runway secured, adding a seasoned leader like Sung Lee to the board is a deliberate and critical step to ensure the company is fully equipped to translate its clinical potential into tangible value for both patients and shareholders.